Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Annayyaon Aug 09, 2021 12:04pm
106 Views
Post# 33672026

RE:RE:RE:New Corporate Update

RE:RE:RE:New Corporate UpdateWe have been holding too long. It would be nice if it's more than just a pattern this time. Unless they announce the phase 1 clinicals starting for PMN310, they have no reason to do another PP as they wouldn't have spent all the $7 million USD ($8.8 million CAD) in the past few months. I did see the serology test revenue estimated time line has been pushed to later in the year, but i am not counting on it as we might be too late. Only way that could drive a lot of revenue is if the government uses it and mandates PMN serology test over others and there's a good chance they might do it as they awarded a lot of money last year to PMN for the antibody research.
M101 wrote: It's just a trading pattern,

demand is up while pp sellers are not so we get a couple of high closes producing a feedback loop. 
 




<< Previous
Bullboard Posts
Next >>